The Straight Version
An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the length of...
The UNHINGED Take
"Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial" — absolute weapon-grade incompetence. Whoever signed off on this circus needs their hard drive checked and their security pass shredded immediately.
The Bottom Line
FAILED / 10
"Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial" — absolute weapon-grade incompetence.
📣 Copy, Paste, Cause Chaos
"Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial" — absolute weapon-grade incompetence. FAILED / 10 https://unhingednews.com/cn/chinese-drug-iza-bren-doubles-lung-cancer-survival #NZElection2026 #UnhingedNZ
That cursed thumbnail up top? Spat out by HyperVision AI in about 4 seconds. Go make your own monstrosity — ruin someone's feed today. 🔥